HemOnc.org - A Human-Curated Hematology/Oncology Reference
HemOnc.org is the largest freely available medical wiki of interventions, regimens, and general information relevant to the fields of hematology and oncology. Any healthcare professional can sign up to contribute; the accuracy and completeness of content is overseen by the Editorial Board. If this is your first time visiting, please start with the the tutorial page, review our philosophy, or just start exploring!
| Regimens: 5,605 | Guidelines: 1,222 | Studies: 7,206 | References: 11,197 |
|---|
| Solid Tumors | Malignant Hematology | Pediatrics | Transplant and IEC | Classical Hematology |
Solid Tumors
Breast Oncology
Early breast cancer (EBC)
- EBC, not otherwise specified (NOS)
- Hormone receptor (HR)-positive EBC
- HER2-positive EBC
- HER2-low EBC
- HR-positive and HER2-positive EBC
- Early triple-negative breast cancer (eTNBC)
Metastatic breast cancer (MBC)
- MBC, NOS
- HR-positive MBC
- HER2-positive MBC
- HER2-low MBC
- HR-positive and HER2-positive MBC
- Metastatic triple-negative breast cancer (mTNBC)
- MBC, central nervous system (CNS) metastases
Breast cancer with molecular alterations
Dermatologic Oncology
Melanoma
Non-melanoma skin cancer (NMSC)
- Cutaneous basal cell carcinoma (BCC)
- Cutaneous squamous cell carcinoma (CSCC)
- Merkel cell carcinoma (MCC)
Endocrine Oncology
Thyroid cancer without molecular alterations
- Thyroid cancer, NOS
- Anaplastic thyroid cancer (ATC)
- Differentiated thyroid cancer (DTC)
- Medullary thyroid cancer (MTC)
Thyroid cancer with molecular alterations
Other endocrine cancers
- Adrenocortical carcinoma
- Neuroendocrine carcinoma (NEC)
- Neuroendocrine tumor (NET)
- Pancreatic NET
- Pheochromocytoma
Gastrointestinal (GI) Oncology
Upper GI tract
- Esophageal cancer, NOS
- Esophageal adenocarcinoma
- Esophageal squamous cell carcinoma (ESCC)
- Gastric cancer, NOS
- HER2-positive gastric cancer
Lower GI tract
- Anal cancer
- Appendiceal tumor
- Colon cancer, NOS
- MSI-H or dMMR colon cancer
- RAS wild-type colon cancer
- Colorectal cancer (CRC), NOS
- BRAF-mutated CRC
- HER2-positive CRC
- MSI-H or dMMR CRC
- RAS wild-type CRC
- Rectal cancer, NOS
- MSI-H or dMMR rectal cancer
- Small bowel adenocarcinoma
Hepatobiliary cancer
- Biliary tract cancer (BTC), NOS
- Cholangiocarcinoma
- Gallbladder cancer
- Hepatocellular carcinoma (HCC)
- Periampullary adenocarcinoma
Pancreatic cancer
Genitourinary (GU) Oncology
Kidney cancer
- Renal cell carcinoma (RCC), NOS
- Clear cell RCC (ccRCC)
- Non-clear cell RCC (nccRCC)
- Papillary RCC
- Sarcomatoid RCC
- VHL-associated RCC
Male genital tract cancer
Urinary tract cancer
Gynecologic Oncology
Ovarian cancer
Other gynecologic cancer
Head and Neck Oncology
All types of head and neck cancer
Mesothelioma
All types of mesothelioma
Neuro-Oncology
Primary CNS malignancies
- Anaplastic glioma
- Craniopharyngioma
- Diffuse midline glioma
- Glioblastoma (GBM)
- Low-grade glioma (LGG)
- Meningioma
- Primary CNS lymphoma (PCNSL)
- Subependymal giant cell astrocytoma (SEGA)
Secondary CNS malignancies
- CNS carcinoma, NOS
- Breast cancer, CNS metastases
- Non-small cell lung cancer, CNS metastases
- CNS leukemia
- Secondary CNS lymphoma (SCNSL)
- CNS melanoma
Sarcoma
Bone sarcoma
Soft tissue sarcoma
- Soft tissue sarcoma (STS), NOS
- Alveolar soft part sarcoma (ASPS)
- Dermatofibrosarcoma protuberans
- Desmoid tumor
- Epithelioid sarcoma
- Gastrointestinal stromal tumor (GIST)
- Inflammatory myofibroblastic tumor (IMT)
- Leiomyosarcoma (LMS)
- Liposarcoma
- PEComa
- Rhabdomyosarcoma (RMS)
- Tenosynovial giant cell tumor (TGCT)
Vascular sarcoma
Thoracic Oncology
Non-small cell lung cancer (NSCLC) without driver alterations
NSCLC with driver alterations
- ALK-positive NSCLC
- BRAF-mutated NSCLC
- c-Met-positive NSCLC
- EGFR-mutated NSCLC
- HER2-mutated NSCLC
- KRAS-mutated NSCLC
- MET-mutated NSCLC
- NRG1-positive NSCLC
- RET-positive NSCLC
- ROS1-positive NSCLC
Other thoracic cancer
- Esophageal cancer
- Malignant pleural mesothelioma (MPM)
- Small cell lung cancer (SCLC)
- Thymoma and thymic carcinoma
Site-agnostic
All types of site-agnostic malignant solid neoplasms
- Carcinoma of unknown primary (CUP)
- Malignant solid neoplasm, BRAF-mutated
- Malignant solid neoplasm, EGFR-mutated
- Malignant solid neoplasm, ERBB2-mutated
- Malignant solid neoplasm, ERBB3-mutated
- Malignant solid neoplasm, microsatellite unstable (MSI-H or dMMR)
- Malignant solid neoplasm, NTRK-mutated
- Malignant solid neoplasm, RET-mutated
- Malignant solid neoplasm, SMO-mutated or PTCH-1-mutated (Hedgehog)
- Malignant solid neoplasm, high tumor mutation burden (TMB-H)
Malignant Hematology
Acute leukemias
- Acute leukemia, KMT2A-rearranged
- Acute myeloid leukemia (AML)
- AML, core-binding factor (CBF-AML)
- AML, FLT3-positive
- AML, IDH1-mutated
- AML, IDH2-mutated
- AML, NPM1-mutated
- Acute promyelocytic leukemia (APL)
- B-cell acute lymphoblastic leukemia (B-ALL)
- B-ALL, Ph+
- T-cell acute lymphoblastic leukemia (T-ALL)
- Blastic plasmacytoid dendritic cell neoplasm (BPDCN)
- CNS leukemia
Myeloproliferative neoplasms and myelodysplastic syndromes
- Chronic myeloid leukemia (CML)
- Chronic myelomonocytic leukemia (CMML)
- Essential thrombocythemia (ET)
- Hypereosinophilic syndrome (HES)
- Myelodysplastic syndrome (MDS)
- Primary and secondary myelofibrosis (PMF/SMF)
- Myeloproliferative neoplasm, accelerated phase (MPN-AP)
- Polycythemia vera (PV)
- Systemic mastocytosis (indolent and aggressive)
Aggressive lymphomas
- Burkitt lymphoma (BL) or Burkitt-like lymphoma
- Classical Hodgkin lymphoma (cHL)
- CNS lymphoma
- Diffuse large B-cell lymphoma (DLBCL)
- Gastric DLBCL
- High-grade B-cell lymphoma (HGBL)
- HIV-associated lymphoma
- Mantle cell lymphoma (MCL)
- Mediastinal gray-zone lymphoma (MGZL)
- Primary mediastinal B-cell lymphoma (PMBL)
- Transformed lymphoma (TL)
Indolent lymphomas
- Chronic lymphocytic leukemia (CLL/SLL)
- Follicular lymphoma (FL)
- Hairy cell leukemia (HCL)
- Hodgkin lymphoma, nodular lymphocyte-predominant (NLP-HL)
- Indolent lymphoma (iNHL), NOS
- MALT lymphoma
- Marginal zone lymphoma (MZL)
- Waldenström macroglobulinemia (WM/LPL)
Plasma cell dycrasias
- Light-chain (AL) amyloidosis
- Multiple myeloma (main page)
- NDMM, induction
- NDMM, consolidation and maintenance
- RRMM
- Plasma cell leukemia (PCL)
- POEMS syndrome
- Smoldering multiple myeloma (SMM)
T-cell and NK-cell neoplasms
- Adult T-cell leukemia-lymphoma (ATLL)
- Anaplastic large cell lymphoma (ALCL)
- Cutaneous T-cell lymphoma (CTCL)
- Extranodal NK- and T-cell lymphoma, nasal type (ENKTCL-NT
- Large granular lymphocytic (LGL) leukemia
- NK- and T-cell lymphoma (NKTCL)
- Peripheral T-cell Lymphoma (PTCL)
- T-cell acute lymphoblastic lymphoma (T-LBL)
- T-cell prolymphocytic lymphoma (T-PLL)
Lymphoproliferative disorders
Histiocytic disorders
- Erdheim-Chester disease (ECD)
- Hemophagocytic lymphohistiocytosis (HLH)
- Langerhans cell histiocytosis (LCH)
- Rosai-Dorfman-Destombes disease
Disease-agnostic
Pediatric Neoplasms
Pediatric CNS malignancies
Pediatric hematologic neoplasms
- B-cell acute lymphoblastic leukemia (B-ALL)
- B-ALL, Ph+
- T-cell acute lymphoblastic leukemia (T-ALL)
- Acute myeloid leukemia (AML)
- Anaplastic large cell lymphoma (ALCL)
- Chronic myeloid leukemia (CML)
- Juvenile myelomonocytic leukemia (JMML)
- Classical Hodgkin lymphoma (cHL)
- Non-Hodgkin lymphoma (NHL)
Pediatric solid tumors
Transplant and Cellular Therapy
Classical Hematology
Hemostasis and thrombosis
- Acquired coagulopathy
- Acquired thrombotic thrombocytopenic purpura (aTTP)
- Antiphospholipid antibody syndrome (APLAS)
- Congenital thrombotic thrombocytopenic purpura (cTTP)
- Hemophilia A
- Hemophilia B
- Heparin-induced thrombocytopenia (HIT)
- Hereditary hemorrhagic telangiectasia (HHT)
- Inherited thrombophilia
- Thrombotic microangiopathy (TMA)
- Venous thromboembolism (VTE)
- von Willebrand disease (vWD)
Cytopenias
- Aplastic anemia
- Autoimmune cytopenia
- Immune thrombocytopenia (ITP)
- Thrombocytopenia in liver disease
- WHIM syndrome
Hemolytic disorders and Hemoglobinopathies
- Atypical hemolytic uremic syndrome (aHUS)
- Warm autoimmune hemolytic anemia (WAIHA)
- Cold agglutinin disease (CAD)
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Pyruvate kinase deficiency (PKD)
- Beta thalassemia
- Sickle cell disease (SCD)
Additional Information
Created as a knowledge base for hematology and oncology providers, HemOnc.org is a collaborative wiki containing details about hundreds of hematology/oncology drugs, and thousands of treatment regimens. Content is added by hematology and oncology professionals, and undergoes continuous peer review.
Any information that one feels would be helpful to other oncology providers is welcome. Visit how to contribute for more details.
Priorities of this project include:
- Creating a database of all approved systemic anticancer therapy agents and supportive medications used in the field of hematology/oncology.
- Creating a database of all standard-of-care systemic anticancer therapy regimens and references to primary literature.
- Sample order sets and examples of supportive medications used with treatment regimens
- Aggregating useful links to existing resources by disease, such as guidelines, information about prognosis, clinical calculators, staging, and patient resources.
- Creating, maintaining, and disseminating a formalized ontology of anticancer drugs and regimens.
Additional possibilities for this project may include:
- Creating synopses of pivotal clinical trials and regimens
- Prioritizing regimens by their efficacy and/or toxicity
- Capturing historical regimens that were standard-of-care before 2005
- Checklists for common clinical scenarios/diseases
- Creating checklists that can be used for patients starting therapy with particular regimens, such as laboratory and imaging (e.g. echocardiogram, PFTs) parameters to monitor and informed consent/discussion of side effects
The field of hematology/oncology is ever-changing, and our hope is that other people will be interested in contributing to make it an increasingly more useful resource. The rapidly evolving nature of the practice demands a more dynamic medium than existing resources can provide and would benefit from being able to be updated in real-time from virtually any computer with internet access. We believe that the familiar format of a Wiki, made popular by sites such as Wikipedia, will significantly help ease-of-use and navigation.